Guidelines for the Treatment of Pulmonary Arterial Hypertension.

Lung
Zoë G S Vazquez, James R Klinger

Abstract

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension characterized by a progressive obliterative vasculopathy of the distal pulmonary arterial circulation that usually leads to right ventricular failure and death. Over the last 25 years, more than a dozen drugs representing five drug classes have been developed and approved for the treatment of this devastating disease. Due to the small number of patients afflicted by PAH, most health care providers have little experience with its management. To address this gap in medical knowledge, treatment guidelines have been developed by professional organizations and expert committees. Over the last few years, these guidelines have been updated to address findings from recent clinical trials and ongoing experience with these drugs. This review provides an update on the most recently published treatment guidelines for pharmacologic treatment of PAH and incorporates them into a contemporary approach to the treatment of this disease.

References

Jul 9, 1992·The New England Journal of Medicine·B W ChristmanJ E Loyd
Feb 1, 1996·The New England Journal of Medicine·R J BarstUNKNOWN Primary Pulmonary Hypertension Study Group
Jun 17, 1998·Journal of the American College of Cardiology·B M WeissO M Hess
Jun 3, 1999·American Journal of Respiratory and Critical Care Medicine·R M TuderN F Voelkel
Mar 19, 2002·American Journal of Respiratory and Critical Care Medicine·Gerald SimonneauUNKNOWN Treprostinil Study Group
Mar 22, 2002·The New England Journal of Medicine·Lewis J RubinGerald Simonneau
Aug 2, 2002·The New England Journal of Medicine·Horst OlschewskiUNKNOWN Aerosolized Iloprost Randomized Study Group
Jul 14, 2004·Chest·David B BadeschUNKNOWN American College of Chest Physicians
Oct 2, 2004·The New England Journal of Medicine·Marc HumbertGérald Simonneau
Apr 9, 2005·American Journal of Respiratory and Critical Care Medicine·John WhartonMartin R Wilkins
Nov 18, 2005·The New England Journal of Medicine·Nazzareno GalièUNKNOWN Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group
Feb 4, 2006·American Journal of Respiratory and Critical Care Medicine·Marc HumbertGérald Simonneau
Dec 19, 2006·American Heart Journal·Joern TongersMarius M Hoeper
May 29, 2008·Circulation·Nazzareno GalièUNKNOWN Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies
Mar 28, 2009·The European Respiratory Journal·G KovacsH Olschewski
May 28, 2009·Circulation·Nazzareno GalièUNKNOWN Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group
May 1, 2010·Journal of the American College of Cardiology·Vallerie V McLaughlinWerner Seeger
Jun 15, 2010·European Heart Journal·David MontaniOlivier Sitbon
Jan 7, 2011·Journal of Clinical Epidemiology·Howard BalshemGordon H Guyatt
Jul 5, 2013·American Journal of Respiratory and Critical Care Medicine·James R KlingerMark T Gladwin
Jul 26, 2013·The New England Journal of Medicine·Hossein-Ardeschir GhofraniUNKNOWN PATENT-1 Study Group
Aug 30, 2013·The New England Journal of Medicine·Tomás PulidoUNKNOWN SERAPHIN Investigators
Feb 7, 2015·The European Respiratory Journal·Nazzareno GalièEkkehard Grünig
Aug 27, 2015·The New England Journal of Medicine·Nazzareno GalièUNKNOWN AMBITION Investigators
Dec 25, 2015·The New England Journal of Medicine·Olivier SitbonP G Williams
Dec 14, 2018·The European Respiratory Journal·Gérald SimonneauRogerio Souza
Dec 14, 2018·The European Respiratory Journal·Nick H KimDavid P Jenkins
Dec 14, 2018·The European Respiratory Journal·Marc HumbertMarlene Rabinovitch
Dec 14, 2018·The European Respiratory Journal·Nazzareno GalièVallerie V McLaughlin
Dec 14, 2018·The European Respiratory Journal·Adaani FrostAdam Torbicki
Dec 14, 2018·The European Respiratory Journal·Nicholas W MorrellJames E Loyd
Dec 14, 2018·The European Respiratory Journal·Jean-Luc VachiéryTeresa De Marco
Dec 14, 2018·The European Respiratory Journal·Olivier SitbonLewis J Rubin
Dec 14, 2018·The European Respiratory Journal·Anton Vonk NoordegraafRobert Naeije
Dec 14, 2018·The European Respiratory Journal·Michael D McGoonBrad A Wong
Dec 14, 2018·The European Respiratory Journal·Erika B RosenzweigRolf M F Berger
Dec 14, 2018·The European Respiratory Journal·Marius M HoeperWalter Klepetko
Dec 14, 2018·The European Respiratory Journal·Steven D NathanWerner Seeger
Dec 16, 2018·The European Respiratory Journal·Nazzareno GalièGerald Simonneau

❮ Previous
Next ❯

Citations

Jan 27, 2021·Lung·Peter V Dicpinigaitis
Jun 19, 2021·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Camila Lopez-CrisostoSergio Lavandero

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Indian Journal of Pediatrics
Erika B Rosenzweig, Robyn J Barst
Therapeutic Advances in Respiratory Disease
Stella S HahnGulrukh Zaidi
Expert Opinion on Emerging Drugs
Erika B Rosenzweig
Advances in Experimental Medicine and Biology
Shuxin LiangHaiyang Tang
European Respiratory Review : an Official Journal of the European Respiratory Society
Luke S Howard
© 2021 Meta ULC. All rights reserved